This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant Neoplasm of Cervix Uteri, C53자궁경부의 악성신생물 (자궁경부암)

Special Copayment Reduction V193 — a copayment of 5% of covered medical care costs applies for 5 years from the date of cancer patient registration (the Cancer Control Act and National Health Insurance special copayment reduction regulations)
Adult onset: very high | ICD-10: C53
Contents (Table of Contents)
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Cervical cancer is one of the longest-recorded malignant tumors in human history. The Egyptian Ebers Papyrus of around 1600 BC contains descriptions of uterine lesions, and around 400 BC Hippocrates described cervical tumors. However, the history of cervical cancer diagnosis and treatment in the modern sense began only in the late 19th century.

In 1925, Hans Hinselmann of Germany developed the colposcope, making early detection of cervical lesions possible. In 1928, the Greek-born American pathologist George Papanicolaou devised a technique for collecting and staining abnormal cells from vaginal secretions, and in 1943, together with Herbert Traut, he formally published the cytology test (Pap smear). From the 1950s, this method spread as a screening test in the United States and Europe and dramatically reduced cervical cancer mortality.

In the 1970s, the German virologist Harald zur Hausen detected HPV DNA in cervical cancer tissue. He identified HPV type 16 (1983) and HPV type 18 (1984) and elucidated the etiological relationship between HPV and cervical cancer, for which he received the Nobel Prize in Physiology or Medicine in 2008. This discovery became the scientific foundation for the development of HPV vaccines. In 2006, Gardasil (a quadrivalent HPV vaccine) was approved by the FDA, and in 2009 Cervarix (a bivalent HPV vaccine) was approved, opening a new era of primary prevention. In 2014, the 9-valent vaccine Gardasil 9 was approved, covering more HPV types.

In the history of treatment, Ernst Wertheim systematized radical hysterectomy in 1898, and radiation therapy was introduced from the 1920s. In 1999, several investigators including J. Rose reported in NEJM that cisplatin-based concurrent chemoradiotherapy (CCRT) was superior to radiation therapy alone, and it became the standard treatment. In 2021, the KEYNOTE-826 trial demonstrated a survival benefit from adding pembrolizumab in recurrent/metastatic cervical cancer, opening the era of immunotherapy. In Korea, a national cervical cancer screening program has been in place since 1988, and the HPV vaccine was included in the National Immunization Program in 2016.

2. Causes

HPV infection is overwhelmingly the most important cause of cervical cancer, and more than 99% of cervical cancers worldwide are associated with HPV.

Human papillomavirus (HPV)

Among high-risk HPV (HR-HPV), HPV 16 and HPV 18 account for about 70% of cervical squamous cell carcinomas and about 70–85% of adenocarcinomas. HPV types 31, 33, 45, 52, and 58 are also detected in a meaningful proportion of cervical cancers. The seven high-risk types (16, 18, 31, 33, 45, 52, 58) covered by the 9-valent HPV vaccine (Gardasil 9) are estimated to be able to prevent about 90% of cervical cancers.

Risk factors

3. Genetics

The genomic characteristics of cervical cancer were comprehensively elucidated through the analysis of the cervical cancer cohort of TCGA (The Cancer Genome Atlas) (2017).

Viral gene integration and carcinogenic mechanism

When the HPV genome (about 8 kb) integrates into the host chromosome, the E2 gene is disrupted and E6/E7 expression becomes deregulated. The E6 protein degrades TP53 in a ubiquitin-dependent manner via the E6AP-TP53 complex, and the E7 protein binds pRb and releases the E2F transcription factor, thereby removing the G1/S cell cycle checkpoint.

Somatic mutations (TCGA, 2017)

Chromosomal abnormalities

3q26 amplification (including PIK3CA, SOX2, TP63) is the most common somatic genetic abnormality in cervical squamous cell carcinoma. 5p and 1q amplifications and 11q, 3p (FHIT), and 2q deletions are frequently reported.

Biomarkers related to immunotherapy

A PD-L1 CPS (Combined Positive Score) ≥ 1 is observed in about 70–80% of cervical cancer patients. TMB-H (≥10 mut/Mb) and dMMR/MSI-H are relatively rare in cervical cancer, but response rates to immune checkpoint inhibitors are high in such patients. In KEYNOTE-826, adding pembrolizumab in patients with PD-L1 CPS ≥ 1 produced a significant survival benefit, with a median OS of 26.4 months (vs. 16.8 months in the placebo group).

4. General epidemiology

Cervical cancer ranks fourth in incidence among cancers in women worldwide, with the burden concentrated in low- and middle-income countries. However, in high-income countries including Korea, incidence is steadily declining due to expanded screening and the introduction of the HPV vaccine.

Global situation

As of 2020, about 604,000 people worldwide were newly diagnosed with cervical cancer and about 342,000 died. Sub-Saharan Africa, Southeast Asia, and Latin America show high incidence and mortality.

Situation in Korea

The age-standardized incidence rate (ASR) of cervical cancer in Korea has steadily declined to about 8 per 100,000 women (as of 2019), less than half of what it was 20 years ago. The 5-year relative survival rate is 80.4% (2017–2021), an intermediate level among major gynecologic cancers. The number of new cervical cancer diagnoses in Korea in 2023 is estimated at about 3,000 (a gynecologic cancer ranking about 2nd–3rd among all cancers in women). Incidence is highest in the 40s–50s, and early onset at age 30 or younger is not uncommon. The national HPV vaccination rate (started in 2016 for girls aged 12) reached about 74% in 2023, and further declines in incidence are predicted.

CategoryFigureNotes
New diagnoses worldwide (2020)About 604,0004th among cancers in women
Korean ASR (2019)~8 per 100,000 womenMore than 50% decrease over 20 years
Korean 5-year survival rate80.4%Based on 2017–2021
Korean HPV vaccination rate (2023)About 74%NIP, for girls aged 12
Proportion attributable to HPV 16+18Squamous cell carcinoma ~70%, adenocarcinoma ~70–85%~90% preventable with the 9-valent vaccine

5. Pathophysiology

At the center of cervical cancer pathogenesis is the multistep progression from persistent HPV infection → intraepithelial lesion (CIN/SIL) → invasive cancer.

HPV infection and intraepithelial lesions

HPV infects the basal epithelial cells of the cervical transformation zone (TZ). The TZ is the squamocolumnar junction, where columnar epithelium transitions to squamous epithelium. The columnar cells in this area are particularly vulnerable to HPV, making it the main site of infection and malignant transformation.

Most HPV infections (about 80–90%) clear spontaneously through immunity. However, when high-risk HPV persists (12–18 months or longer), low-grade squamous intraepithelial lesions (LSIL/CIN 1) develop, and some of these progress to high-grade lesions (HSIL/CIN 2–3). If untreated, CIN 3 progresses to invasive cervical cancer within 30 years in about 30% of cases.

Molecular carcinogenic mechanism

Degradation of TP53 by HPV E6 and inactivation of pRb by E7 are the key mechanisms. pRb inactivation activates transcription of E2F-dependent genes (PCNA, CDC6, MCM proteins, etc.), causing abnormal cell proliferation. E7 also binds DNMT1 to induce epigenetic changes and confers unlimited proliferative capacity on cells through telomerase (TERT) activation. E6 also degrades cell polarity proteins such as DLG1 and SCRIB, causing impaired cell polarity and adhesion and thereby increasing invasiveness.

Pathogenesis by histologic type

Squamous cell carcinoma arises mainly in the TZ and is most strongly associated with HPV type 16. Adenocarcinoma, arising from the columnar cells of the endocervix, is more strongly associated with HPV type 18. The relative proportion of adenocarcinoma is tending to increase as squamous cell carcinoma decreases with expanded screening.

6. Symptoms

Early cervical cancer (FIGO stage I–IIA) is often asymptomatic and found incidentally on screening. When symptoms begin to appear, local progression or invasion has usually advanced considerably.

Main symptoms

7. Signs

Gynecologic examination findings

Findings of pelvic invasion

Findings of distant metastasis

8. Screening

Cervical cancer is a representative cancer that can be detected early and prevented thanks to its long precancerous stage (CIN) and effective screening methods. The Korean National Cancer Screening Program provides free cervical cytology every 2 years for women aged 20 and older.

Cervical cytology (Pap smear / Liquid-Based Cytology)

Cells are collected from the cervical TZ by conventional smear cytology or liquid-based cytology (LBC) to check for abnormal cells. Results are read using the Bethesda system and classified as NILM (normal), ASC-US, LSIL, ASC-H, HSIL, AGC, AIS, cancer cells, and so on. Sensitivity is about 55–80% and specificity about 90%, and cumulative sensitivity improves with repeated testing.

HPV testing

High-risk HPV testing (HR-HPV testing) is more sensitive than cytology (85–95%). In Korean national screening, a system combining cytology + HPV co-testing or primary HPV testing alone for women aged 30 and older has been expanded in stages since 2015. When HPV is negative, the risk of developing CIN 3+ within 10 years is very low.

Cervical cancer screening recommendations (Korea)

9. Diagnosis

Histological diagnosis

Colposcopy-directed punch biopsy is the standard diagnostic method. Abnormal cytology (HSIL, AGC) + normal colposcopic findings: perform endocervical curettage (ECC) or LEEP/conization. ECC is added when an endocervical lesion is suspected. Histological type classification: squamous cell carcinoma (about 70–75%), adenocarcinoma (about 20–25%), adenosquamous carcinoma, small cell neuroendocrine carcinoma, and others.

Imaging and staging

FIGO 2018 staging

StageDefinition
IA1Depth of stromal invasion <3 mm
IA2Depth of stromal invasion 3–5 mm
IB1Clinical lesion <2 cm or depth of stromal invasion >5 mm, <2 cm
IB2Clinical lesion 2–4 cm
IB3Clinical lesion ≥4 cm, confined to the cervix
IIA1Invasion of the upper 2/3 of the vagina, <4 cm
IIA2Invasion of the upper 2/3 of the vagina, ≥4 cm
IIBParametrial invasion, not reaching the pelvic wall
IIIAInvasion of the lower 1/3 of the vagina
IIIBPelvic wall invasion or hydronephrosis/nonfunctioning kidney
IIIC1Pelvic lymph node metastasis (confirmed by imaging or pathology)
IIIC2Para-aortic lymph node metastasis
IVAInvasion of the bladder/rectal mucosa
IVBDistant metastasis

10. Treatment

Early stage (FIGO IA1–IB1): surgery

Stage IA1 (no lymphovascular invasion): cone biopsy or simple hysterectomy. When lymphovascular space invasion (LVSI) is present, consider adding radical hysterectomy.

Stage IA2–IB1: radical hysterectomy (Wertheim-Meigs operation) + pelvic lymphadenectomy ± para-aortic lymph node sampling. For those wishing to preserve fertility, radical trachelectomy + pelvic lymphadenectomy is performed (stage IB1, tumor less than 2cm).

Locally advanced stage (FIGO IB2–IVA): concurrent chemoradiotherapy (CCRT)

Standard treatment: cisplatin 40 mg/m² once weekly × 5–6 weeks + pelvic external beam radiation (45–50 Gy) + intracavitary brachytherapy boost. It is recommended as standard in the 2021 ESGO guidelines, and the Korean KSGO guidelines make the same recommendation.

Recurrent/metastatic (FIGO IVB, recurrence): systemic anticancer therapy

Postoperative adjuvant therapy

When intermediate- to high-risk factors are present after surgery (positive margins, lymph node metastasis, parametrial invasion): adjuvant CCRT or radiation therapy is given. When intermediate-risk Sedlis criteria (LVSI + depth of stromal invasion + tumor size) are met: adjuvant radiation therapy.

11. Prognosis

5-year survival rate by stage

FIGO stage5-year survival rate (global average)Notes
Stage IA93~98%With curative treatment
Stage IB–IIA75~90%Surgery or CCRT
Stage IIB–III50~70%CCRT standard
Stage IVA15~25%Individualized treatment plan
Stage IVB (first-line pembrolizumab era)mOS 26.4 monthsKEYNOTE-826
Overall 5-year survival rate in Korea80.4%2017–2021

Poor prognostic factors

12. Prevention

HPV vaccination (primary prevention)

The HPV vaccine is the most effective means of primary prevention of cervical cancer. Since 2016, Korea's NIP has provided 2 free doses of the bivalent (Cervarix) or quadrivalent (Gardasil) HPV vaccine to girls aged 12. The 9-valent HPV vaccine (Gardasil 9) is available at additional cost, and the Ministry of Health and Welfare (MOHW) is currently reviewing a switch to the 9-valent vaccine in the NIP. Adult women (aged 26 or younger) are also eligible for vaccination, and for ages 27–45 vaccination is considered based on clinical judgment. The WHO recommends 2 doses at ages 9–14 or 3 doses at age 15 or older, and HPV testing before vaccination is not necessary.

Cervical cancer screening (secondary prevention)

Early detection through cervical cytology or HPV testing is key. Korean national cancer screening: cytology once every 2 years for women aged 20 and older. When CIN 2–3 is found, progression to invasive cancer is prevented by treatment such as LEEP or conization.

Management of behavioral risk factors

The WHO declared that if HPV vaccination coverage of 90%, screening coverage of 70%, and treatment access of 90% are achieved by 2030, cervical cancer can be eliminated as a public health problem within the coming generations (2020 Global Strategy to Accelerate the Elimination of Cervical Cancer).

13. References

  1. Sung H, et al. Global Cancer Statistics 2020. CA Cancer J Clin. 2021;71(3):209-249.
  2. KEYNOTE-826 Final OS: Colombo N, et al. J Clin Oncol. 2023. doi:10.1200/JCO.23.00914
  3. KEYNOTE-826 East Asia Subgroup. J Gynecol Oncol. 2025;36:e110. ejgo.org
  4. Korean Society of Gynecologic Oncology. Clinical Practice Guidelines for Cervical Cancer: 2025 Update. J Gynecol Oncol. 2025;36:e70.
  5. Korean Society of Gynecologic Oncology. Clinical Practice Guidelines for Cervical Cancer. PMC10948982. 2024.
  6. TCGA Research Network. Integrated Genomic and Molecular Characterization of Cervical Cancer. Nature. 2017;543(7645):378-384.
  7. Rose PG, et al. Concurrent Cisplatin-Based Radiotherapy for Locally Advanced Cervical Cancer. N Engl J Med. 1999;340(15):1144-1153.
  8. Predicted Cervical Cancer Prevention: Impact of National HPV Vaccination Program in South Korea. Cancer Res Treat. 2024. PMC11261207.
  9. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2023. PMC13093029. 2026.
  10. WHO Global Strategy to Accelerate the Elimination of Cervical Cancer, 2020.
  11. Coleman RL, et al. Tisotumab vedotin for recurrent or metastatic cervical cancer. N Engl J Med. 2021;385(20):1856-1867.